Mink therapeutics reports q1 2025 results and highlights clinical & strategic progress

New york, may 15, 2025 (globe newswire) -- mink therapeutics, inc. (nasdaq: inkt), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer t (inkt) cell therapies, today announced its financial results for the first quarter of 2025 and provided a business update highlighting continued clinical progress and strategic developments across its inkt platform. the company will host a conference call and webcast today at 8:30 a.m. et.
INKT Ratings Summary
INKT Quant Ranking